SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending, fueled by intense community engagement around its multi-chain presence across Cronos, Solana, and Ethereum. Enthusiasts are actively discussing its deflationary burn mechanism and organic growth, positioning it as a potential "king of memes" within the crypto space.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending due to community excitement surrounding a rumored collaboration with POL and its recent integration with ACH, signaling a meaningful expansion of its real-world utility. Investors are actively watching Dash, an original privacy coin, to potentially mirror the strong upward movement of Zcash amidst a broader resurgence of interest in the privacy token sector. Many anticipate it is poised for significant gains and breaking key resistance levels.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is actively trending due to its strategic pivot into the high-growth obesity drug market following a recent acquisition and ongoing pipeline developments, including upcoming vaccine trial readouts. The community is keenly focused on the company's ability to execute on these growth drivers and navigate patent expiration pressures, while its strong dividend yield remains a key discussion point for long-term investors.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is a top trending stock, driven by high anticipation for its presentation at the J.P. Morgan Healthcare Conference and the imminent PMDA approval in Japan. The community is buzzing about recent positive clinical data, particularly for pancreatic and skin cancer, which showcases the revolutionary Alpha DaRT technology's potential and is attracting significant institutional interest. This momentum, marked by robust volume and new price levels, underscores investor belief in the company's trajectory within the targeted alpha therapy sector.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is trending strongly as the community buzzes about recent partnerships, notably with World Liberty Financial, and the integration of USD1 for payroll and card services. Investors are enthusiastically discussing ZBCN's robust real-world utility in on-chain payments, low token dilution, and ISO 20022/MiCA compliance, with many anticipating significant growth fueled by its upcoming "Super App" and expanding integrations.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending due to surging institutional interest, marked by significant stablecoin inflows and new ETF filings from major financial players. The community is actively discussing large whale accumulations and Solana's growing role as a high-performance blockchain for various applications. Its expanding ecosystem and unique speed position it as a strong contender in the digital asset space, with anticipation for clearer regulatory frameworks.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amid escalating speculation that Sanofi is preparing an improved takeover offer after an initial bid was rejected. Community discussion points to the company's confidence in its lead drug, AXPAXLI, and an accelerated NDA pathway as key reasons for seeking a higher valuation, with many anticipating a significant premium ahead of upcoming Phase 3 data. This activity highlights broader interest in long-acting therapies for the wet AMD market.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing intense investor interest following Saudi FDA approval for its ANKTIVA drug in both bladder and lung cancer, complemented by a reported 700% year-over-year revenue surge. The community is eagerly anticipating a significant short squeeze, fueled by enthusiasm for ANKTIVA's chemotherapy-free approach and its potential to revolutionize cancer treatment as a 

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is trending as it recently achieved new all-time highs, reflecting broad market strength and investor confidence. The community actively discusses VTI as a 'painfully simple yet effective' core holding for diversified, long-term growth, often comparing its steady performance to more concentrated growth funds. This positive sentiment is underpinned by favorable U.S. growth outlooks and an increasing risk appetite across various market sectors.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is trending due to its strategic expansion through acquisitions, recently adding Dynavax and Blueprint Medicines to bolster its vaccine and immunology pipelines. The community is actively discussing a potential sweetened takeover offer for Ocular Therapeutix, alongside ongoing interest in Sanofi's partnership with Novavax. These moves, coupled with the continued strong performance of key drugs like Dupixent, highlight Sanofi's focus on pipeline growth in critical therapeutic areas.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

 Energy ETFs in Spotlight as US Natural Gas Prices Set to Fall This Year

Energy ETFs like XLE come into focus as EIA forecasts a 2026 US natural gas price dip, followed by a sharp rebound expected in 2027.

Cooling towers of a nuclear power plant in Oxford, UK.

SMR Stock Back In Focus As Trump Pushes Big Tech To Share Power Prices, Help Build Plants

NuScale is seeing increased chatter after Trump’s push for tech giants to share the responsibility in expanding grids soars.

Equity

A Chevron gas station is shown on October 23, 2023 in Austin, Texas. (Photo by Brandon Bell/Getty Images)

Chevron Stock Pulls Ahead Of Big Oil Peers As Venezuela Bets Resurface Under Trump

CVX shares have risen for five straight sessions, keeping them ahead of ExxonMobil and ConocoPhillips in early 2026 gains.

<ul class="summary-bullets"><li>Jefferies expects Chevron to report adjusted earnings per share (EPS) of $1.45, or about 2% higher than consensus.</li><li>Analyst Byrne expects investors to focus on developments in Venezuela, TCO (Tengizchevroil) production in Kazakhstan, an update on the El Segundo fire, and the gas-to-AI outlook.&nbsp;</li><li>Chevron is expected to report its fourth-quarter (Q4) 2025 earnings on Jan. 30, 2026.</li></ul><p>Jefferies has hiked Chevron Corp.’s (CVX) price target on expectations of the company to report earnings higher than street consensus.</p><p>Analyst Lloyd Byrne at the firm raised Chevron’s price target to $189 from $174 before and maintained a ‘Buy’ rating on the shares, according to TheFly.</p><p>Jefferies expects Chevron to report adjusted earnings per share (EPS) of $1.45, or about 2% higher than consensus, as per the note. Chevron is expected to report its fourth-quarter (Q4) 2025 earnings on Jan. 30, 2026.</p><p>Shares of CVX rose over 2% on Wednesday at the time of writing.</p><h2 class="st-heading-2">Future Insights</h2><p>Byrne expects investors to focus on developments in Venezuela, TCO (Tengizchevroil) production at the Tengiz field in Kazakhstan, an update on the El Segundo crude oil fire, and the gas-to-AI outlook.</p><p>U.S. President Donald Trump’s push for American oil majors to boost oil production from Venezuela has propelled market interest in related companies, including Chevron, which is currently the only major American oil company still operating in Venezuela.</p><p>Last year, Chevron’s 50%-owned affiliate TCO began oil production at the Future Growth Project (FGP) in Kazakhstan, marking a major expansion that is expected to boost output by about 260,000 barrels per day and ramp total production toward 1 million barrels of oil equivalent per day. The company said the milestone would materially increase free cash flow and deliver long-term economic benefits.</p><p>The company is also expected to provide an update on the fire that occurred at its El Segundo refinery in Oct. 2025.</p><h2 class="st-heading-2">Oil Boost</h2><p>As per a Bloomberg report, U.S. intervention in Venezuela is likely to boost crude output in the country by roughly 50% in the next decade, according to industry consultant Enverus. Production is likely to touch about 1.5 million barrels a day by 2035, as per the report.</p><p>Meanwhile, oil prices have been gaining on the back of rising geopolitical tensions including supply disruption fears from a potential U.S. attack on Iran as well as production cuts.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVX">CVX stock</a> remained in the ‘bullish’ territory over the past day amid ‘normal’ message volumes.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_at_9_53_02_PM_png_1c39e37da8.webp" alt="On Stocktwits, retail sentiment around CVX stock remained in the ‘bullish’ territory over the past day amid ‘normal’ message volumes." width="1269" height="157"></figure><p>Shares of CVX have gained 6.49% in the past year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i><br>&nbsp;</p>

The Chevron logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 5, 2025. (Photo by Jaque Silva/NurPhoto via Getty Images)

Chevron’s Price Target Upped At Jefferies On Higher Earnings Forecast

Analyst Lloyd Byrne at Jefferies raised Chevron’s price target to $189 from $174 before and maintained a ‘Buy’ rating.

Traders work on the floor of the New York Stock Exchange during morning trading on December 10, 2025, in New York City, ahead of the Federal Reserve’s rate decision. 

Why Did ELAB Stock Surge Nearly 8% After-Hours Today?

After a not-so-great 2025, a push to buy a nuclear company has put PMGC Holdings back on investors’ radar.

U.S. President Donald Trump addresses a House Republican retreat at The John F. Kennedy Center for the Performing Arts on January 06, 2026 in Washington, DC. 

Trump Fuels Oil Glut Fears With Plan To Bring Up To 50M Barrels Of Venezuelan Crude To US

Big Oil and oilfield services names also pulled back after Monday’s Venezuela-fueled rally.

Energy ETFs in Spotlight as Trump Vows to Control Venezuela's Oil

Energy ETFs like XLE draw focus after Trump vows US control of Venezuela's oil, drawing attention to firms tied to the nation's vast reserves. 

Despite a quarterly loss, NuScale remains bullish on nuclear energy’s potential, fueled by future outook on Trump’s energy policy priorities. | Source: Pixabay

NuScale Stock Gets A Hot Start To 2026 — Can America’s Nuclear Push Finally Turn It Profitable?

Even though NuScale’s financials do not show clear signs of investor interest, buzz about the U.S. government's efforts to boost nuclear energy in the country is driving optimism.

An offshore oil platform is seen at sunset on February 9, 2024 near Huntington Beach, California.

Chevron, Exxon, Other Crude Players Add $50B In Market Cap As Trump Opens Door To Big Oil's Return In Venezuela

Trump said companies would be repaid by the government or future production revenue, easing concerns over upfront capital risk.

Detailed Fundamental Analysis - XLE

Below is Validea's ETF fundamental report for SPDR Energy Select Sector SPDR Fund (XLE). The report looks at XLE's exposure to the major investing factors including value, quality, momentum and low...

Current Price	$47.77
Prev Close	$47.61
Open	$47.56
Dividend Yield	N/A
50-Day Moving Average	$45.36
Beta	N/A
Avg. Volume	27.08M
PE Ratio	N/A

52-Week High	$48.65
52-Week Low	$37.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

XLE
Energy Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLE News

XLEEnergy Select Sector SPDR Fund